Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three formulations of acetaminophen and codeine phosphate tablets commonly referred to as "T1", "T2", and "T3". Each formulation contains a fixed amount of acetaminophen (a non-opioid analgesic and antipyretic) combined with increasing doses of codeine phosphate (an opioid analgesic). The typical strengths are: - T1: Acetaminophen 300 mg + Codeine Phosphate 8 mg - T2: Acetaminophen 300 mg + Codeine Phosphate 15 mg - T3: Acetaminophen 300 mg + Codeine Phosphate 30 mg These medications are used for the short-term relief of mild to moderate pain. Acetaminophen works by inhibiting prostaglandin synthesis in the central nervous system, reducing pain and fever. Codeine acts primarily as a mu-opioid receptor agonist in the CNS to provide analgesia but can cause dependence if used long-term[6][7]. These products may also contain caffeine in some markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + codeine (T1 + T2 + T3 combination).